Borui Biopharmaceutical Taixing key facts
- Manufacturer of pharmaceutical raw materials and intermediates designed for therapeutic and industrial applications.
- Notable investors include Fuzhe Capital, Zhejiang State-Owned Capital Operation, BrightGene Bio-Medical Technology Company, China Cinda Asset Management.
- Status: Privately Held (backing).
Who backs Borui Biopharmaceutical Taixing
4- ·Watch Borui Biopharmaceutical Taixing: the Monday email on marks, rounds and moves
Borui Biopharmaceutical Taixing funding rounds
No funding rounds for Borui Biopharmaceutical Taixing are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Borui Biopharmaceutical Taixing investors
4 investors are on record for Borui Biopharmaceutical Taixing, including Fuzhe Capital, Zhejiang State-Owned Capital Operation, BrightGene Bio-Medical Technology Company and China Cinda Asset Management.
About Borui Biopharmaceutical Taixing
Manufacturer of pharmaceutical raw materials and intermediates designed for therapeutic and industrial applications. The company offers large-scale production of active pharmaceutical ingredients, chemical intermediates, and biologically derived compounds and development capabilities, enabling global pharmaceutical enterprises and healthcare markets to secure reliable supply chains, maintain consistent quality standards, accelerate product development, and strengthen competitiveness.
- Sector
- Healthcare
- HQ
- Taixing, China
- Founded
- 2007
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Borui Biopharmaceutical Taixing doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.